Dr. Martens’ (DOCS) “Sector Perform” Rating Reaffirmed at Royal Bank Of Canada

Dr. Martens (LON:DOCS)‘s stock had its “sector perform” rating restated by Royal Bank Of Canada in a note issued to investors on Tuesday,London Stock Exchange reports. They presently have a GBX 100 target price on the stock. Royal Bank Of Canada’s target price points to a potential upside of 38.31% from the stock’s current price.

Separately, Berenberg Bank decreased their price target on shares of Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of GBX 105.

Dr. Martens Stock Performance

LON DOCS opened at GBX 72.30 on Tuesday. The firm has a market cap of £699.28 million, a price-to-earnings ratio of 42.53, a PEG ratio of 6.40 and a beta of 0.22. The company has a 50 day moving average of GBX 65.39 and a 200-day moving average of GBX 70.22. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.27. Dr. Martens has a 1-year low of GBX 56.70 and a 1-year high of GBX 100.87.

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Tuesday, May 19th. The company reported GBX 4.20 earnings per share for the quarter. The company had revenue of £764.90 million during the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. On average, equities analysts forecast that Dr. Martens will post 2.5809394 earnings per share for the current fiscal year.

Insider Transactions at Dr. Martens

In other Dr. Martens news, insider Ije Nwokori sold 204,051 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of GBX 66, for a total value of £134,673.66. Insiders have purchased 930 shares of company stock valued at $59,984 over the last quarter. 2.81% of the stock is currently owned by company insiders.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.